Back to VCNXVaccinex, Inc. (VCNX)View full pipeline
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Phase 3Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Human Papillomavirus (HPV) Infection
View Full LandscapeDrug Information
Target Indication
Human Papillomavirus (HPV) Infection
Clinical Trial
NCT06632912Last updated: 6/26/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)Phase 3
HPV InfectioN
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)Phase 3
Norovirus Infections
pepinemab + pembrolizumabPhase 2
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
VX15/2503Phase 2
Huntington's Disease
PepinemabPhase 2
Alzheimer Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts